Newron Needs To Up Ante In Large-Scale Schizophrenia Studies
Newron has reported positive Phase IIa data for schizophrenia drug evenamide but Phase III will be critical for the add-on therapy to demonstrate a more robust treatment effect to justify its use on top current treatments.
You may also be interested in...
Newron has raised $27m via a private placement to fund late-stage development of its novel schizophrenia drug and to license new assets that will bulk up its limited clinical pipeline.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.